148 related articles for article (PubMed ID: 30941953)
21. [Interpretation of the updates of NCCN 2017 version 1.0 guideline for colorectal cancer].
Chen G
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Jan; 20(1):28-33. PubMed ID: 28105616
[TBL] [Abstract][Full Text] [Related]
22. Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy.
Ulivi P; Scarpi E; Chiadini E; Marisi G; Valgiusti M; Capelli L; Casadei Gardini A; Monti M; Ruscelli S; Frassineti GL; Calistri D; Amadori D; Passardi A
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28598398
[TBL] [Abstract][Full Text] [Related]
23. Targeted therapy for metastatic colorectal cancer.
Price TJ; Tang M; Gibbs P; Haller DG; Peeters M; Arnold D; Segelov E; Roy A; Tebbutt N; Pavlakis N; Karapetis C; Burge M; Shapiro J
Expert Rev Anticancer Ther; 2018 Oct; 18(10):991-1006. PubMed ID: 30019590
[TBL] [Abstract][Full Text] [Related]
24. When more is worse in clinical research and clinical practice.
Tassinari D; Tombesi P; Sartori S
Am J Clin Oncol; 2010 Aug; 33(4):424. PubMed ID: 20689366
[No Abstract] [Full Text] [Related]
25. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
[TBL] [Abstract][Full Text] [Related]
26. Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015.
Price TJ; Thavaneswaran S; Burge M; Segelov E; Haller DG; Punt CJ; Arnold D; Karapetis CS; Tebbutt NC; Pavlakis N; Gibbs P; Shapiro JD
Expert Rev Anticancer Ther; 2016 May; 16(5):557-71. PubMed ID: 27010906
[TBL] [Abstract][Full Text] [Related]
27. [The RAS paradox of the EGFR-targeted therapy in colorectal cancer].
Tímár J; Láng I
Magy Onkol; 2008 Jun; 52(2):185-91. PubMed ID: 18640895
[TBL] [Abstract][Full Text] [Related]
28. The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside.
Zaniboni A; Formica V
Cancer Chemother Pharmacol; 2016 Aug; 78(2):233-44. PubMed ID: 27091467
[TBL] [Abstract][Full Text] [Related]
29. Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013.
Price TJ; Segelov E; Burge M; Haller DG; Tebbutt NC; Karapetis CS; Punt CJ; Pavlakis N; Arnold D; Gibbs P; Shapiro JD
Expert Rev Anticancer Ther; 2014 Dec; 14(12):1477-93. PubMed ID: 25138900
[TBL] [Abstract][Full Text] [Related]
30. The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway.
Russo A; Rizzo S; Bronte G; Silvestris N; Colucci G; Gebbia N; Bazan V; Fulfaro F
Oncology; 2009; 77 Suppl 1():57-68. PubMed ID: 20130433
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
[TBL] [Abstract][Full Text] [Related]
32. Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices.
Landsman-Blumberg PB; Carter GC; Johnson BH; Sedgley R; Nicol SJ; Li L; Shankaran V
Clin Colorectal Cancer; 2014 Sep; 13(3):178-84. PubMed ID: 25065655
[TBL] [Abstract][Full Text] [Related]
33. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
Pietrantonio F; Petrelli F; Coinu A; Di Bartolomeo M; Borgonovo K; Maggi C; Cabiddu M; Iacovelli R; Bossi I; Lonati V; Ghilardi M; de Braud F; Barni S
Eur J Cancer; 2015 Mar; 51(5):587-94. PubMed ID: 25673558
[TBL] [Abstract][Full Text] [Related]
34. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
Van Cutsem E; Köhne CH; Láng I; Folprecht G; Nowacki MP; Cascinu S; Shchepotin I; Maurel J; Cunningham D; Tejpar S; Schlichting M; Zubel A; Celik I; Rougier P; Ciardiello F
J Clin Oncol; 2011 May; 29(15):2011-9. PubMed ID: 21502544
[TBL] [Abstract][Full Text] [Related]
35. RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014.
Lièvre A; Merlin JL; Sabourin JC; Artru P; Tong S; Libert L; Audhuy F; Gicquel C; Moureau-Zabotto L; Ossendza RA; Laurent-Puig P; Ducreux M
Dig Liver Dis; 2018 May; 50(5):507-512. PubMed ID: 29396127
[TBL] [Abstract][Full Text] [Related]
36. Should anti-EGFR mAbs be discontinued for conversion surgery in untreated right-sided metastatic colorectal cancer? A systematic review and meta-analysis.
Chen D; Zhang X; Gao G; Shen L; Xie J; Qian X; Wang H
World J Surg Oncol; 2018 Oct; 16(1):200. PubMed ID: 30296945
[TBL] [Abstract][Full Text] [Related]
37. Impact of Primary Tumor Localization on the Efficacy of Bevacizumab in Metastatic Colorectal Cancer.
Jordan F; Grundmann N; Schenkirsch G; Märkl B; Messmann H; Anthuber M; Schmid C; Trepel M
Anticancer Res; 2018 Sep; 38(9):5539-5546. PubMed ID: 30194214
[TBL] [Abstract][Full Text] [Related]
38. Treatment sequencing of metastatic colorectal cancer based on primary tumor location.
Temraz S; Mukherji D; Nassar F; Moukalled N; Shamseddine A
Semin Oncol; 2021 Apr; 48(2):119-129. PubMed ID: 34120762
[TBL] [Abstract][Full Text] [Related]
39. Challenges That Hinder the Translation of Clinical Advances Into Practice: Results From an International Assessment in Colorectal Cancer.
Lazure P; Marshall JL; Hayes SM; Murray S
Clin Colorectal Cancer; 2016 Mar; 15(1):54-66. PubMed ID: 26341411
[TBL] [Abstract][Full Text] [Related]
40. Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019.
Lau DK; Burge M; Roy A; Chau I; Haller DG; Shapiro JD; Peeters M; Pavlakis N; Karapetis CS; Tebbutt NC; Segelov E; Price TJ
Expert Rev Anticancer Ther; 2020 Apr; 20(4):251-270. PubMed ID: 32186929
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
